390
The collapse of CureVac continues on Wall Street, where the stock loses more than 43% and travels just above $ 53. Triggering the downward spiral was the news that CureVac’s Covid vaccine candidate appears to be only 47% effective in the last phase of clinical trials, failing to meet the German biotech group’s expectations and casting a shadow over potential delivery to all. ‘European Union of hundreds of millions of doses. The disappointing results come from a provisional analysis of data on 134 Covid-19 cases in a study involving around 40,000 volunteers in Europe and Latin America.